Gilead's remdesivir could be $7.7bn blockbuster - analyst

An influential analyst has upped his previously cautious assessment of the sales potential of Gilead’s COVID-19 drug remdesivir, saying sales could reach $7.7 billion in 2022. 

FDA clears emergency use of Roche test for COVID-19 'cytokin...

BMS launches COVID-19 delayed MS drug Zeposia in US

Bristol-Myers Squibb opted not to launch its new multiple sclerosis therapy Zeposia when it got FDA

AZ claims FDA okay for Brilinta in coronary artery disease p...

AstraZeneca’s anti-platelet drug Brilinta has been cleared in the US for a major new indication, preventing a first heart attack or stroke in high-risk patients with coronary a

Novartis closes on EU approval for breast cancer drug Piqray

Novartis has moved nearer to claiming approval for its PI3K inhibitor Piqray for breast cancer in the EU, one of a crop of new drugs that the company thinks have blockbuster sa

NICE recommends Roche's Tecentriq in ES-SCLC following price...

NICE has said that Roche’s Tecentriq (atezolizumab) plus chemotherapy should be funded by the NHS as an option for untreated extensive-stage small-cell lung cancer (ES-SCLC) in second draft